Industry Sectors
In addition to a growing body of industry and sector analyses, we provide a rich resource of RSS feeds, covering all the major sectors including aerospace and defence, transport, energy, technology, manufacturing and financial services.
Google, Under Attack, May Close China Site
The search giant has clashed with Chinese authorities and says other large companies have been targeted by 'sophisticated' attacks. It plans to stop censoring search results in China
Categories: Technology
Google Phone Threatens Droid More Than iPhone
The only thing revolutionary about Google's Nexus One is its business model, says Rich Jaroslovsky
Categories: Technology
Hybrid Fuels selects FDA approved lab for Azul Instan
Hybrid Fuels has selected a FDA approved laboratory to manufacture all new orders of Azul Instan, developed by Nouveau Life Pharmaceuticals.
Categories: Pharmaceuticals
Merck receives FDA approval for type 2 diabetes therapy
Merck, known as MSD outside the US and Canada, has received FDA approval for JANUMET XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets for type 2 diabetes.
Categories: Pharmaceuticals
Insero enters licensing deals to produce Huperzine
Insero Health, a developer of novel therapies derived from natural products, has signed an exclusive license agreement with Yale University for an efficient synthetic manufacturing process of Insero's Huperzine.
Categories: Pharmaceuticals
TCI to open new distribution center in US
TCI America, an organic chemical manufacturing and distribution company, has announced the opening of a new distribution center in Montgomeryville, Pennsylvania, in April 2012.
Categories: Pharmaceuticals
SGI, IDT partner to manufacture synthetic gene products
Synthetic Genomics (SGI) and Integrated DNA Technologies (IDT) have entered into an agreement to manufacture, market, and commercialize small synthetic gene products.
Categories: Pharmaceuticals
Geron concludes patient enrollment in cancer drug trial
Geron has completed patient enrollment in the randomized Phase 2 clinical trial of Imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC).
Categories: Pharmaceuticals
FDA approves Bayer radium-223 chloride expanded access program
Bayer HealthCare has received the US Food and Drug Administration approval to proceed with its expanded access program for the investigational drug radium-223 chloride.
Categories: Pharmaceuticals
COTI develops COTI-2 Phase 1 oral formulation
Critical Outcome Technologies (COTI) has developed Phase 1 oral formulation candidates for COTI-2, a potentially first-in-class non-ATP competitive modulator/inhibitor of AKT/AKT2.
Categories: Pharmaceuticals
Celerion selects Verified participant verification system
Celerion, a provider of innovative early stage drug development solutions, has deployed Verified Clinical Trials' VCT Verify to ensure accurate participant identification and qualification for clinical research.
Categories: Pharmaceuticals
Nuvo launches Synera in US
Nuvo Research, a specialty pharmaceutical company, has launched Synera (70mg lidocaine/ 70mg tetracaine/ heated topical patch) in the US.
Categories: Pharmaceuticals
Eusa acquires Asparec development rights from Alizé Pharma
Eusa Pharma has acquired the exclusive worldwide development and commercialisation rights to Asparec for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.
Categories: Pharmaceuticals
DelMar VAL-083 drug gets FDA orphan drug status
The US Food and Drug Administrations' Office of Orphan Products Development has granted orphan drug designation for DelMar Pharma's VAL-083, used to treat glioma, including glioblastoma multiforme (GBM).
Categories: Pharmaceuticals
OptiNose to begin Phase III trials with intranasal technology
OptiNose, a drug delivery company, has filed an investigational new drug (IND) with the FDA to use sumatriptan delivered with its novel drug delivery technology, in December 2011.
Categories: Pharmaceuticals
Mylan gets tentative FDA nod for generic Lipitor
Mylan Laboratories (formerly Matrix Laboratories) has received tentative FDA approval for abbreviated new drug application (ANDA) for Atorvastatin Calcium Tablets, 10mg (base), 20mg (base), 40mg (base) and 80mg (base).
Categories: Pharmaceuticals
Sucampo, Takeda Phase III OBD trial meets primary endpoint
Sucampo Pharmaceuticals (SPI) and Takeda Pharmaceuticals have reported that lubiprostone met the primary endpoint in a Phase III clinical trial for the treatment of opioid-induced bowel dysfunction (OBD).
Categories: Pharmaceuticals
Nautilus receives US patent for Diclofenac formulations and methods
Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company, has received US patent entitled, Diclofenac formulations and methods of use.
Categories: Pharmaceuticals
Masitinib found superior to standard GIST treatment: AB Science reports
AB Science's investigational drug, Masitinib has showed improved overall survival in patients with Gleevec-resistant gastrointestinal stromal tumors (GIST).
Categories: Pharmaceuticals
Foundation Medicine wins CLIA certification for genomic sequencing laboratory
Foundation Medicine, a molecular information company, has received the Clinical Laboratory Improvement Amendments (CLIA) certification for its genomic sequencing laboratory in Cambridge, Massachusetts.
Categories: Pharmaceuticals
Lead the discussion in your industry
If you would like to discuss your industry with your peers, why not set up an individual disvcussion group for your sector. We can create both private and public groups where you can swap information and practical tips. If you would like to set up a group please contact the editor, Janice McGinn
The Bottom Line:If Mr Cable has his way...
"If Mr Cable had his way, all the big banks would be broken up and bonuses would be virtually eliminated - a sure-fire way in my view of guaranteeing an end to the UK’s ability to compete as an international financial centre. Let’s not forget that this is a man who is on record as saying that everyone who works in a bank has an ‘aristocratic lifestyle’ clearly demonstrating his lack of understanding of the sector." A tough line on bankers’ bonuses could make a brain drain of financial talent a distinct possibility, warns Paul Marsden. Read more